Reduction of Aversive Learning Rates in Pavlovian Conditioning by Angiotensin II Antagonist Losartan: A Randomized Controlled Trial.

What Was Tested

Researchers studied Angiotensin II in this randomized controlled trial publication.

Computational reinforcement learning models were used to investigate learning dynamics.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, both men and women.

In a double-blind, randomized, placebo-controlled design, the researchers tested 45 (18 female) healthy volunteers during a baseline session, after application of losartan or placebo (drug session), and during a follow-up session.

During each session, participants engaged in a task in which they had to predict the probability of an electrical stimulation on every trial while the true shock contingencies switched repeatedly between phases of high and low shock threat.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Angiotensin II.

Some participants received a placebo instead of Angiotensin II, giving a reference point.

The researchers investigated the influence of the angiotensin receptor blocker losartan on aversive Pavlovian conditioning using a probabilistic learning paradigm.

What Was Measured

The subject headings attached to it are Losartan, Conditioning, Classical, Angiotensin II Type 1 Receptor Blockers, Avoidance Learning and Blood Pressure.

The authors tagged it with the keywords Angiotensin receptor, Anxiety, Aversive learning fear and Reinforcement learning.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Biological psychiatry), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.